LifeMD, Inc.

LifeMD, Inc. (Nasdaq: LFMD) has announced a rescheduling of its third quarter 2026 earnings release and conference call. The event will now take place on Thursday, November 12, 2026. The company expects to issue its earnings press release around 4:05 p.m. Eastern time, followed by the conference call at 4:30 p.m. Eastern time. Details for accessing the rescheduled conference call have been provided.

LifeMD reported Q2 2026 revenue of $47.3 million, meeting its guidance, and an adjusted EBITDA loss of $3.5 million, which improved sequentially. The company saw significant gross margin expansion and subscriber growth, driven by a transition to branded GLP-1 therapies and scaling its in-house pharmacy. However, LifeMD revised its full-year 2026 revenue and adjusted EBITDA guidance downwards, citing higher-than-anticipated near-term profitability impact from strategic shifts, but expects a return to positive adjusted EBITDA in H2 2026.

LifeMD, Inc. reported a net loss of $7.86 million for the second quarter of 2026, a significant increase from the $2.40 million loss in the same period last year. Telehealth revenue for Q2 2026 decreased to $47.28 million from $49.02 million year-over-year. For the six months ended June 30, 2026, the company's net loss widened to $17.51 million from $3.36 million in the prior year. The company also noted an accumulated deficit of $246.1 million and negative working capital of $4.5 million as of June 30, 2026, but expects to fund operations for at least the next 12 months.

LifeMD reported Q2 2026 revenue of $47.3 million, meeting its guidance range, but an adjusted EBITDA loss of $3.5 million, which was below its guided range. The company saw strong subscriber growth and improved gross margin, driven by a shift to branded GLP-1 therapies and in-house pharmacy scaling. However, it revised its full-year 2026 revenue and adjusted EBITDA guidance downwards, while still expecting a return to positive adjusted EBITDA in the second half of 2026.

LifeMD, Inc. reported Q2 2026 revenue of $47.3 million, meeting its guidance range, and an adjusted EBITDA loss of $3.5 million, a 21% sequential improvement. The company saw gross margin expand to 89% and total active subscribers grow 20% year-over-year to 356,000, including 108,000 Weight Management Program subscribers. LifeMD also launched a co-marketing collaboration for XYOSTED® and expects to return to positive adjusted EBITDA in the second half of 2026. However, the company revised its full-year 2026 revenue guidance downwards to $205.5 million to $212.5 million and adjusted EBITDA guidance to negative $6.0 million to breakeven.

LifeMD, Inc. announced it will report its financial results for the second quarter and first six months ended June 30, 2026, after the U.S. financial markets close on August 5, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. Eastern time to discuss the results.

LifeMD, Inc. announced a strategic co-marketing collaboration with Halozyme's wholly owned subsidiary, Antares Pharma, Inc. LifeMD will serve as the exclusive telehealth co-marketing partner for the XYOSTED self-pay program, an FDA-approved once-weekly subcutaneous testosterone auto-injector. The program, launching in July 2026 in 37 states, aims to expand access to hypogonadism treatment through virtual evaluations, preferred pharmacy dispensing, and consumer education, all for a transparent monthly price of approximately $249.

LifeMD, Inc. announced the appointment of Umesh Sripad as its new Chief Technology Officer (CTO), effective immediately. Mr. Sripad will be responsible for leading the company's technology strategy, platform transformation, AI enablement, cybersecurity, and data infrastructure as LifeMD continues its rapid expansion. He brings over two decades of experience from prominent companies like PetMeds, Bed Bath & Beyond, and IKEA USA, and his expertise is expected to be invaluable as LifeMD aims to scale its platform to serve millions of patients. As an inducement for his employment, Mr. Sripad was granted 150,000 restricted stock units, with vesting tied to both continued service and performance targets.

LifeMD, Inc. announced that its management will participate in two upcoming investor conferences. The company will attend the LD Micro Invitational XVI Conference from May 17-19, 2026, where management will present on May 19th and be available for one-on-one meetings. Following this, LifeMD management will participate in the B. Riley Securities 26th Annual Investor Conference on May 20-21, 2026, holding one-on-one meetings on May 20th.

LifeMD, Inc. reported a significant increase in net loss attributable to common stockholders, reaching $9.65 million for Q1 2026, compared to a $0.96 million loss in Q1 2025. Telehealth revenue slightly decreased to $50.16 million. The company also disclosed non-compliance with a Consolidated Interest Coverage Ratio covenant under its new $30 million credit facility, primarily due to a 34% increase in selling and marketing expenses. Discussions with Citizens Bank for an amendment or waiver are ongoing.